6533b85bfe1ef96bd12bbdb8
RESEARCH PRODUCT
SAKK 36/13 ‐ IBRUTINIB PLUS BORTEZOMIB AND IBRUTINIB MAINTENANCE FOR RELAPSED AND REFRACTORY MANTLE CELL LYMPHOMA: FINAL REPORT OF A PHASE I/II TRIAL OF THE EUROPEAN MCL NETWORK
Christoph RennerGeorg HessStefan DirnhoferSimone FerreroChristoph DriessenSebastian BöttcherUrban NovakG. ScheubeckSafaa M. RamadanMichèle VoegeliS. GadientThomas MenterM. FehrUlrich MeyM. DreylingC. BoccominiN. MachEmanuele ZuccaK. EckhardtAnne CairoliSämi SchärThilo Zandersubject
Cancer ResearchBortezomibbusiness.industryHematologyGeneral Medicinechemistry.chemical_compoundPhase i iiOncologychemistryIbrutinibCancer researchmedicineRefractory Mantle Cell Lymphomabusinessmedicine.drugyear | journal | country | edition | language |
---|---|---|---|---|
2021-06-01 | Hematological Oncology |